Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

@article{Bass2010BiomarkersAP,
  title={Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.},
  author={Michael Brian Bass and Steven I. Sherman and Martin Jean Schlumberger and Michael T. Davis and Lisa Kivman and Huan-Mei Khoo and Kimberly H Notari and Matthew L. Peach and Yong-jiang Hei and Scott Patterson},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2010},
  volume={95 11},
  pages={5018-27}
}
CONTEXT Antiangiogenic therapies have shown potential in the treatment of advanced thyroid cancer, but it is uncertain which patients are most likely to benefit from therapy. OBJECTIVE This prespecified exploratory analysis investigated whether baseline levels and/or changes in circulating biomarkers could predict tumor response and/or progression-free survival (PFS) among patients enrolled in a phase 2 study of motesanib in advanced thyroid cancer. DESIGN/SETTING/PATIENTS Patients with… CONTINUE READING
39 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Similar Papers

Loading similar papers…